CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer

Table 3 The tumor volume with anti-PD-1 and/or anti-CD25 associated with anti-TGF-β treatment in different periods

Cohorts	Number	Day 7	Day 14	Day 21	Day 28	Day 35
Anti-PD-1	5	0.49 ± 0.45	3.02 ± 3.38	10.81 ± 9.82	39.71 ± 27.06	163.50 ± 117.02
Anti-TGF-β⁺ anti-CD25	5	1.56 ± 1.68	7.61 ± 7.08	34.94 ± 30.67	55.28 ± 41.42	129.87 ± 29.75
Anti-PD-1⁺ anti-TGF-β⁺ anti-CD25	5	1.93 ± 1.74	1.46 ± 2.09	1.84 ± 4.04	6.32 ± 14.13	13.31 ± 29.76
Multiple comparision p value	1 vs. 2	0.205	0.227	0.132	0.502	0.906
	1 vs. 3	0.139	0.411	0.114	0.050	0.043
	2 vs. 3	0.742	0.099	0.044	0.037	0.046

ISSN: 1479-5876